Ventyx Biosciences VTYX Stock
Ventyx Biosciences Price Chart
Ventyx Biosciences VTYX Financial and Trading Overview
| Ventyx Biosciences stock price | 14 USD |
| Previous Close | 14 USD |
| Open | 13.99 USD |
| Bid | 13.98 USD x 2000 |
| Ask | 14 USD x 200 |
| Day's Range | 13.99 - 14 USD |
| 52 Week Range | 0.78 - 25 USD |
| Volume | 5.4M USD |
| Avg. Volume | 3.62M USD |
| Market Cap | 1B USD |
| Beta (5Y Monthly) | 1.274 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13 USD |
VTYX Valuation Measures
| Enterprise Value | 816.41M USD |
| Trailing P/E | N/A |
| Forward P/E | -8.941459 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 5.2180395 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -7.012 |
Trading Information
Ventyx Biosciences Stock Price History
| Beta (5Y Monthly) | 1.274 |
| 52-Week Change | 907.19% |
| S&P500 52-Week Change | 28.42% |
| 52 Week High | 25 USD |
| 52 Week Low | 0.78 USD |
| 50-Day Moving Average | 13.23 USD |
| 200-Day Moving Average | 6.78 USD |
VTYX Share Statistics
| Avg. Volume (3 month) | 3.62M USD |
| Avg. Daily Volume (10-Days) | 2.71M USD |
| Shares Outstanding | 71.75M |
| Float | 47.85M |
| Short Ratio | 1.84 |
| % Held by Insiders | 4.21% |
| % Held by Institutions | 84.49% |
| Shares Short | 4.48M |
| Short % of Float | 6.92% |
| Short % of Shares Outstanding | 6.25% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2024 |
| Most Recent Quarter (mrq) | September 30, 2025 |
| Next Fiscal Year End | December 31, 2025 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -28.46% |
| Return on Equity (ttm) | -45.35% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -116438000 USD |
| Net Income Avi to Common (ttm) | -106607000 USD |
| Diluted EPS (ttm) | -1.49 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 192.64M USD |
| Total Cash Per Share (mrq) | 2.7 USD |
| Total Debt (mrq) | 10.02M USD |
| Total Debt/Equity (mrq) | 5.24 USD |
| Current Ratio (mrq) | 17.861 |
| Book Value Per Share (mrq) | 2.683 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -87752000 USD |
| Levered Free Cash Flow (ttm) | -47460248 USD |
Profile of Ventyx Biosciences
| Country | United States |
| State | CA |
| City | San Diego |
| Address | 12790 El Camino Real |
| ZIP | 92130 |
| Phone | 760-407-6511 |
| Website | https://ventyxbio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 83 |
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Its pipeline includes small molecule therapeutics to treat inflammation across cardiometabolic disorders, neurodegenerative diseases, and inflammatory disorders. The company's portfolio of NLRP3 inhibitors includes VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor that is in a Phase 2a trial for patients with early Parkinson's disease and is in a Phase 2 trial for patients with obesity and additional risk factors for cardiovascular disease. Ventyx Biosciences, Inc. was incorporated in 2018 and is headquartered in San Diego, California. As of March 4, 2026, Ventyx Biosciences, Inc. operates as a subsidiary of Eli Lilly and Company.
Q&A For Ventyx Biosciences Stock
What is a current VTYX stock price?
Ventyx Biosciences VTYX stock price today per share is 14 USD.
How to purchase Ventyx Biosciences stock?
You can buy VTYX shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Ventyx Biosciences?
The stock symbol or ticker of Ventyx Biosciences is VTYX.
Which industry does the Ventyx Biosciences company belong to?
The Ventyx Biosciences industry is Biotechnology.
How many shares does Ventyx Biosciences have in circulation?
The max supply of Ventyx Biosciences shares is 71.75M.
What is Ventyx Biosciences Price to Earnings Ratio (PE Ratio)?
Ventyx Biosciences PE Ratio is 0.00000000 now.
What was Ventyx Biosciences earnings per share over the trailing 12 months (TTM)?
Ventyx Biosciences EPS is 0 USD over the trailing 12 months.
Which sector does the Ventyx Biosciences company belong to?
The Ventyx Biosciences sector is Healthcare.
Ventyx Biosciences VTYX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| Stlmt ID US Tech Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| US Tech Global Select Market Com NQGS | 13180.97 USD — |
-0.87
|
— — | 13139.79 USD — | 13316.81 USD — | — - | — — |
| US Tech Biotechnology NBI | 5807.22 USD — |
+1.87
|
— — | 5685.34 USD — | 5809.82 USD — | — - | — — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
| US Tech US 700 Small Cap Index NQUS700SC | 2992.49 USD — |
-1.38
|
— — | 2986.86 USD — | 3018.97 USD — | — - | — — |
- {{ link.label }} {{link}}